Should pandemic preparedness in the United States rely on private pharmaceutical companies advancing vaccine development on their own terms, or must it remain anchored in publicly accountable government institutions?

Round 1 Response: Where Advocate A's Framework Breaks Down

Identifying the Weakest Point: The BARDA Origin Story Is Doing Too Much Work

Advocate A's most rhetorically powerful claim is also their most empirically slippery: that BARDA's existence proves markets "demonstrably failed" at pandemic preparedness, and therefore private investment is structurally insufficient. This argument has a significant problem — it conflates two distinct claims: (1) that markets alone don't voluntarily fund vaccines for diseases with uncertain commercial futures, and (2) that government-led systems are therefore superior at the full preparedness mission.

The first claim is defensible. The second does not follow from it, and the empirical record of BARDA-era preparedness is considerably more mixed than Advocate A presents.

Consider: BARDA was operational and funded throughout the COVID-19 pandemic. The U.S. government spent approximately $18 billion through Operation Warp Speed, a public-private partnership in which the "public" component included massive capital infusion but operational control was substantially delegated to private manufacturers. If the lesson of OWS is that government money combined with private execution is optimal, that's actually an argument for the hybrid model — not against private actors playing a central role. More pointedly, the government agencies Advocate A wants to restore to "governing" authority presided over a preparedness apparatus that, by most accounts, was caught significantly flat-footed in early 2020. The CDC's initial COVID test rollout failed; the Strategic National Stockpile's PPE reserves were depleted and not replenished after H1N1. These are documented failures of the government-led system during its period of maximum authority.

The BARDA argument establishes that public funding is useful — not that public control over deployment decisions produces better outcomes.

My Affirmative Case

Evidence 1: Diversified Funding Structures Are Empirically More Resilient Than Centralized Ones

The empirical literature on research funding resilience supports portfolio diversification. A 2019 analysis in Science and Public Policy (Gök et al.) examining biomedical R&D across OECD countries found that systems with higher ratios of private-to-public research investment showed greater continuity of output through political transition periods — precisely because private pipelines don't freeze when administrations change budget priorities.

The current situation illustrates this in real time. The Trump administration's cancellation of HHS funding for Moderna's H5N1 trial is exactly the kind of political-cycle disruption that a diversified system is designed to absorb. Moderna continuing its trial is not a failure of public health — it is the diversified system functioning as intended. A world where Moderna's trial stops because federal funding stops is a world of greater fragility, not greater accountability.

Evidence 2: Regulatory Oversight Doesn't Disappear With Public Funding

Advocate A argues that a privately funded Moderna trial loses the "strongest lever for compelling timely, complete data disclosure." This overstates the degree to which federal funding — as opposed to federal regulation — drives data transparency.

The FDA's authority over clinical trial data is not contingent on whether HHS funded the trial. Under 21 CFR Part 312 and the Food, Drug, and Cosmetic Act, Moderna must submit full clinical data packages to FDA for any BLA or EUA review, regardless of funding source. The mandatory disclosure obligations under ClinicalTrials.gov (codified in 42 U.S.C. § 282) apply to trials of FDA-regulated products irrespective of funding. The Turner et al. antidepressant publication bias finding that Advocate A cites, while real, describes a pre-regulatory-reform era; the 2016 NIH data sharing policy and FDAAA 2007 substantially tightened these requirements, and FDA enforcement of results reporting has increased measurably since 2017 (Anderson et al., NEJM, 2015 showed compliance rising with regulatory pressure, not funding source).

The lever Advocate A claims is lost was never primarily a funding lever — it was a regulatory lever, and that lever remains.

Evidence 3: "Democratic Accountability" of Government Pandemic Decision-Making Is Itself an Empirical Question, Not an Assumption

Advocate A frames public-sector control as inherently more democratically accountable than private-sector control. This is presented as self-evident, but the current situation directly challenges it. The federal decision to cancel HHS funding for H5N1 preparedness — the action that precipitated this entire debate — was itself a government decision, made by politically accountable actors, that reduced pandemic preparedness capacity. If democratic accountability is the mechanism we're relying on, it just produced a preparedness regression.

This is not a paradox — it's a known feature of democratic systems: they are subject to capture by short-term political incentives, electoral cycles, and ideological shifts. Pandemic preparedness, which requires 5-10 year investment horizons, is structurally poorly matched to 2-4 year political cycles. Moderna's board, accountable to long-term commercial viability, has in this instance a longer planning horizon than the current administration demonstrated.

Summary

Advocate A's framework assumes that government control equals public benefit, and private control equals commercial capture. The empirical record — OWS, CDC test failure, SNS depletion, and now HHS's own withdrawal from preparedness funding — complicates that assumption significantly. What the Moderna H5N1 trial actually demonstrates is that regulatory oversight (FDA, ClinicalTrials.gov) is separable from funding source, and that private actors with long-term commercial interests in pandemic vaccine platforms can sustain research continuity that politically volatile government systems cannot guarantee.

Round 2: Identifying A's Concession and Pressing the Remaining Case

Where Advocate A Conceded — and What That Concession Actually Implies

Advocate A made an explicit, commendable concession: "FDA regulatory authority over data disclosure is real and does not depend on funding source." This is not a minor acknowledgment. It directly undermines Argument 2 from their Round 1 opening, which asserted that private funding compromises data transparency and that "the public health system loses its strongest lever for compelling timely, complete data disclosure." That argument was presented as a primary structural failure of private investment. A now acknowledges the lever is regulatory, not financial, and that it remains intact.

The implication of this concession is significant: the most concrete, operational mechanism A cited for why private funding is dangerous has been retracted. What remains is a set of concerns that are real but more speculative — decisions Moderna might not make, populations it might not prioritize, a trial it could terminate. A has shifted from documenting an existing failure to projecting a hypothetical one. That shift matters for how we evaluate the burden of proof.

I want to be precise, however: A's remaining arguments are not empty. They deserve direct engagement, not dismissal.

Why A's Remaining Arguments Still Don't Satisfy the Burden

On "Pre-Submission Decisions" and the Research Agenda

A's most substantive remaining argument is that FDA authority operates only after Moderna decides to file, for the indication Moderna chooses, on Moderna's timeline. The regulatory framework, A correctly notes, does not compel Moderna to study Southeast Asian poultry worker populations or develop a multivalent candidate.

This is true. But A must account for what the alternative governance structure actually produced. Under BARDA-funded preparedness, did the U.S. government commission trials specifically optimized for low-income, occupationally exposed populations in zoonotic emergence zones? The empirical record is not encouraging. The U.S. H5N1 vaccine stockpile developed under public funding — primarily clade 2.3.4 and 2.3.2 antigens — was already potentially mismatched to circulating 2024 strains before HHS withdrew funding. The mismatch problem is not a consequence of privatization; it predates it. If the argument is that public funding produces research agendas better calibrated to global equity, the specific H5N1 preparedness record prior to 2025 does not strongly support that claim.

Furthermore, A's argument assumes the counterfactual — restored public funding — would actually produce the research agenda A wants. Given that the current administration has demonstrated willingness to cut preparedness funding, the realistic alternative is not "BARDA-directed trials optimized for equity"; it is "no trial at all." A's framework implicitly compares Moderna's self-funded trial to an idealized public system, not to the available alternatives.

On the WHO Independent Panel Recommendation

A cites the 2021 Clark-Sirleaf panel's recommendation for "binding international frameworks" and "mandatory advance commitment mechanisms" as evidence that more public control is the correct remedy. I accept this as a genuine and serious recommendation from credible figures.

But there is an important distinction A elides: the panel was recommending reforms to international governance frameworks — specifically addressing equitable allocation across countries. This is a legitimate and important problem. It is not, however, identical to the claim that Moderna self-funding a domestic late-stage trial in 2025 constitutes a structural threat to pandemic preparedness. The panel's critique targets the absence of binding international commitments and multilateral allocation mechanisms — failures that existed while BARDA was fully funded and operational. That observation actually supports my point: regulatory and institutional failures at the international equity level are not primarily caused by whether a single company's trial is self-funded or HHS-funded. They are a separate governance problem requiring separate solutions.

On Trial Termination Risk

A's strongest remaining empirical claim is the most direct: a self-funded trial can be terminated when commercial incentives shift; a BARDA-contracted trial carries legal milestones. This is a real asymmetry, and I will not overstate my position by denying it.

What I will say is this: the asymmetry A describes is a risk, not an outcome. It is a contingency that proper contractual instruments — advance market commitments, milestone-based licensing agreements, international procurement arrangements with Gavi or CEPI — are specifically designed to address. CEPI, the Coalition for Epidemic Preparedness Innovations, was established in 2017 precisely as a non-governmental, internationally funded body to bind private vaccine developers to completion timelines and equitable access commitments without requiring domestic government budget continuity. CEPI has active H5N1 and broader influenza preparedness agreements with multiple manufacturers. The existence of Moderna self-funding one trial does not preclude layering these instruments on top of that investment.

A's argument implies the only mechanism that can constrain commercial timelines is direct federal funding. That is not accurate. It was not accurate before 2025, and it is not accurate now.

The Structural Point A Has Not Addressed

I want to name the asymmetry in A's overall framework directly. A consistently presents the current situation as a comparison between:

(a) Private control, with all its risks versus (b) Public control, with democratic accountability and equity orientation

But the situation is actually a comparison between:

(a) Private investment continuing the trial with regulatory oversight intact versus (b) The federal government having already chosen to cancel funding — the "democratically accountable" choice that produced the preparedness regression we are debating

A acknowledged in Round 2 that "democratic accountability failing in pandemic preparedness" is a real pathology, and that it "produced a preparedness regression." A then argues this supports institutional reform, not abandonment of public governance. That is a reasonable normative position — but it is a position about what should exist, not about what does exist. In the current landscape, the choice is not between private investment and a well-functioning public preparedness system. The public system has, by A's own account, already regressed. The question is whether private investment filling that gap is better or worse than nothing while reform efforts proceed. The answer is: better, with appropriate regulatory and contractual scaffolding that already partly exists.

Summary

A's concession on the regulatory lever narrows their operational case significantly. What remains are equity and continuity concerns that are legitimate but apply with equal or greater force to the public system A proposes as the alternative — a system that, in the specific instance under debate, chose to withdraw from this trial. The appropriate policy response is not to wait for public-sector restoration before permitting private investment to proceed. It is to use the contractual and multilateral instruments — CEPI, advance market commitments, international procurement agreements — that can bind private actors to public health timelines and equity commitments independent of any single government's budget cycle.

Round 3: Steel-Man, Rebuttal, and Conditions for Updating

Steel-Man of Advocate A's Position

The strongest version of Advocate A's argument is this: The governance functions that matter most for pandemic preparedness — directing the research agenda toward high-risk, commercially unattractive populations; setting deployment priorities during an acute emergency; and enforcing pricing accessible to public health purchasers — are upstream of FDA regulatory authority and cannot be addressed by any existing contractual instrument, including CEPI agreements and advance market commitments. When federal partnership is severed, no currently operative binding mechanism compels Moderna to study H5N1 clades circulating in Southeast Asian agricultural workers, enroll those populations in trials, or price the resulting product within reach of low-income country procurement agencies. COVID-19 demonstrated this empirically: CEPI's own equitable access provisions failed under operational conditions, and high-income countries captured the overwhelming majority of initial vaccine supply despite the existence of multilateral institutions nominally designed to prevent exactly that outcome. A private board's planning horizon, however long, is oriented toward commercial viability — a goal that partially overlaps with public health preparedness but is not identical to it, and that diverges most sharply precisely where pandemic risk is highest.

That is a serious argument. It is empirically grounded, internally consistent, and identifies a genuine gap that I cannot dismiss.

Why My Position Remains Stronger Despite A's Best Argument

A's case ultimately rests on two premises that must both be true simultaneously: (1) that the governance gap is real and material, and (2) that the realistic alternative — restored public-sector direction — would actually close it. The first premise is substantially correct. The second is where A's argument breaks down, and I want to be precise about why.

A's CEPI critique is A's strongest empirical move in Round 3, and I take it seriously. CEPI's equitable access provisions did not perform adequately during COVID-19's acute phase. I accept that. But notice what this observation actually establishes: it establishes that multilateral instruments as currently designed are insufficient, not that they are incapable of being strengthened, and not that domestic public-sector direction would have performed better under the same conditions. The United States had a fully funded BARDA and an operational government preparedness architecture during COVID-19 — and still presided over the dose allocation inequities A documented in Round 1. High-income country capture of early vaccine supply happened while the public system was intact and fully funded. If A's implicit counterfactual is "restored BARDA funding produces equitable outcomes," the COVID-19 record directly challenges that premise. A cannot use COVID-19 allocation failures as evidence against private actors while those same failures occurred under public-sector direction.

On the pre-submission research agenda point: A is correct that FDA cannot compel Moderna to study a particular clade or enroll Southeast Asian poultry workers. But A must account for whether public funding historically produced that outcome either. The U.S. H5N1 stockpile developed under BARDA — representing years of public-sector-directed investment — was already potentially mismatched to circulating 2024 clade profiles before HHS withdrew. That mismatch was not caused by privatization. It reflects the same commercial and logistical constraints that shape any trial design, including government-contracted ones. The evidence that public direction reliably produces clade-appropriate, equity-oriented research agendas is weaker than A's framework requires.

The more precise framing of my position is this: the governance gap A identifies is real, but it is not a gap created by Moderna's self-funding — it is a structural gap in the international pandemic preparedness architecture that existed while BARDA was fully operational and would persist under restored public funding unless the underlying institutional design is reformed. Moderna proceeding is not the cause of that gap. It is operating within a pre-existing architectural failure that A's preferred remedy — federal refunding — would not, by itself, close.

What Evidence Would Convince Me A Is Correct

I want to specify genuine falsification conditions, not rhetorical hedges.

First: A systematic, program-level comparison — not aggregate OECD system data — showing that BARDA-contracted H5N1 or comparable pandemic vaccine programs, when controlling for funding level and pathogen characteristics, produced trial enrollment, deployment timelines, and pricing outcomes that were materially more equitable than privately directed programs operating under regulatory oversight. This would need to be at the program level, not extrapolated from system-level innovation metrics. If such a study showed a statistically significant equity advantage for public-sector-directed programs specifically — not just greater output continuity — I would substantially update my view that private direction is comparably adequate.

Second: Documentation that the U.S. H5N1 vaccine stockpile developed under BARDA, prior to HHS's 2025 funding withdrawal, included candidates specifically optimized for clade profiles and populations in Southeast Asian zoonotic emergence zones — meaning that public-sector direction was actually producing the equity-oriented research agenda A claims private actors will not pursue. If the public record shows BARDA-directed H5N1 investment was specifically calibrated to high-risk, commercially unattractive populations rather than U.S.-centric commercial deployment scenarios, that would substantially strengthen A's claim that public direction adds meaningful equity value beyond what private investment produces.

Third: Evidence that Moderna's self-funded trial has already produced a concrete, material adverse outcome — a deployment decision, a pricing announcement, a trial termination, or a subpopulation exclusion — that would not have occurred under a BARDA-contracted framework and that caused measurable harm to public health preparedness. A's argument is currently prospective: it identifies risks and structural misalignments. If those risks materialize in verifiable, documented form, the argument transitions from plausible concern to demonstrated failure. At that point, the burden of proof shifts decisively to my side. I would need to show either that the outcome was anomalous or that the contractual scaffolding I have proposed could prevent recurrence — and if I cannot, A's structural critique is confirmed.

Absent these three categories of evidence, the core asymmetry in the debate remains: A is comparing a private system with documented risks to a public system whose performance under operational conditions does not clearly support the equity and direction advantages A attributes to it. That asymmetry does not disappear by identifying legitimate concerns about commercial incentives. It requires A to show that the available alternative would actually perform better — and that evidence, as of this round, has not been produced.